The present invention provides a lactic acid bacteria starter comprising: Streptococcus thermophilus; and a lactic acid bacterium of the Lactobacillaceae other than Lactobacillus delbrueckii.

The present invention relates to a strain having liver function improving activity, and a use thereof. Specifically, the present invention relates to a health food composition for improving liver function and a pharmaceutical composition for improving liver function, which contain, as an active ingredient, one or more strains selected from the group consisting of a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, and a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a lysate thereof or a culture product thereof. The strain of the present invention shows excellent activity in inhibiting the activity of alanine aminotransferase (ALT) or aspartate aminotransferase (AST), inhibiting an increase in the concentration of total cholesterol or triglycerides in the liver, and inhibiting fat accumulation in the liver, thereby being effectively usable in the preparation of a food composition and a pharmaceutical composition for improving liver function.

The present invention is related to the field of reddening of food products. In particular the present invention relates to the preservation of nitrate reductase activity of frozen and/or dried lactic acid bacteria culture or Micrococcaceae culture.

The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient. In addition, the present invention relates to a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, each of which comprises the novel strain of the present invention, a lysate thereof, or a culture thereof as an active ingredient.

The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient. In addition, the present invention relates to a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, each of which comprises the novel strain of the present invention, a lysate thereof, or a culture thereof as an active ingredient.

A composition comprising combination of salt, sugar and lactic acid bacteria as an active ingredient to treat vaginosis. The composition showed potent antibacterial activity through various experiments, for example, (1) the indirect inhibitory activity test from the growth of vaginosis causing bacteria by determining the change of pH and lactic acid level; (2) the direct inhibitory activity test from the growth of vaginosis causing bacteria by determining the susceptibility of test sample; (3) brief clinical tests, and finally confirmed that the combination showed potent antibacterial activity in the test. Accordingly, the combination may be useful to alleviate and treat vaginosis in the form of a pharmaceutical composition, health functional food, food additive, topical composition, and detergent composition.

The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient. In addition, the present invention relates to a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, each of which comprises the novel strain of the present invention, a lysate thereof, or a culture thereof as an active ingredient.

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a pharmaceutical composition or a food product obtained by culturing Gluconacetobacter hansenii or Acetobacter pasteurianus in a medium. Also disclosed is a pharmaceutical composition and a food product that each include a metabolite of Gluconacetobacter hansenii or Acetobacter pasteurianus for reducing uric acid levels in a subject and methods for producing the pharmaceutical composition and the food product.

A composition containing a Lactobacillus pentosus TUA4337L strain (accession number: NITE BP-1479), characterized in that the strain has proliferation ability in the small intestines and/or the large intestine, and preferably the small intestines, after having survived in the intestinal tract. Since the composition of the present invention contains lactic acid bacteria having proliferation ability in the intestinal tract, when ingested in the body, the lactic acid bacteria survive to the intestinal tract and proliferate, whereby the fat absorption can be blocked, and the weight gains can be blocked, so that the composition can be suitably used for the purposes of dieting effects.

A composition containing a Lactobacillus pentosus TUA4337L strain (accession number: NITE BP-1479), characterized in that the strain has proliferation ability in the small intestines and/or the large intestine, and preferably the small intestines, after having survived in the intestinal tract. Since the composition of the present invention contains lactic acid bacteria having proliferation ability in the intestinal tract, when ingested in the body, the lactic acid bacteria survive to the intestinal tract and proliferate, whereby the fat absorption can be blocked, and the weight gains can be blocked, so that the composition can be suitably used for the purposes of dieting effects.